Xenetic Reveals $141M Santersus Deal Terms: 85/15 Split, New 'SNTS' Ticker
XBIO sits 32% above its 52-week low of $1.87.
Summary
Xenetic's updated investor presentation quantifies the Santersus reverse merger: $141M total valuation, 85/15 ownership split favoring Santersus, ~14.55M new shares to be issued, and a new 'SNTS' Nasdaq ticker.
Key Events · M&A and Partnerships · XBIO
-
Transaction Valuation Disclosed
Xenetic valued at $21 million, Santersus at $120 million, for a combined $141 million pro forma valuation under the Share Exchange Agreement dated September 14, 2026.
-
Massive Dilution for Existing Holders
Santersus shareholders will own ~85% of the combined company; Xenetic holders retain only ~15%. Approximately 14.55 million new Xenetic shares will be issued at closing, bringing total post-closing shares to ~17.1 million.
-
New Nasdaq Ticker 'SNTS'
The combined company is expected to trade on Nasdaq under the ticker symbol 'SNTS', with Santersus continuing as the operating business.
-
Clinical Milestones Detailed
Sepsis program targets EU market launch Q2 2028 and US launch Q4 2029; SLE pivotal study starts Q4 2026; DNase LBCL proof-of-concept data expected Q2 2027.
Analysis · XBIO · Life Sciences
This 8-K attaches an updated investor presentation that quantifies the previously announced Santersus reverse merger. Xenetic is valued at $21 million and Santersus at $120 million, with Santersus holders receiving approximately 85% of the combined company. The presentation discloses roughly 14.55 million new Xenetic shares will be issued at closing, bringing total post-closing shares to about 17.1 million — a massive dilution event for existing Xenetic holders, who will own only ~15% of the combined entity. The combined company will trade under ticker 'SNTS' on Nasdaq. The presentation also lays out clinical milestones: EU market launch for the sepsis program targeted for Q2 2028, US launch Q4 2029, and DNase proof-of-concept data in Q2 2027. For a micro-cap company with a market cap under $6 million, this transaction fundamentally transforms the equity story — existing shareholders are effectively ceding control to Santersus stakeholders.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XBIO was trading at $2.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $1.87 to $13.93. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.